# IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

> **NCT05970263** · PHASE4 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- COPD

## Interventions

- **DRUG:** Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
- **OTHER:** External Comparator

## Key facts

- **NCT ID:** NCT05970263
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-19
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment challenges
- **Last updated:** 2024-02-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970263, "IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05970263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*